Key clinical point: Use of remote electrical neuromodulation (REN) every other day is a safe and effective preventive treatment for migraine.
Major finding: REN was superior to placebo in reducing the mean number of migraine days per month (P < .001), moderate or severe headache days per month (P = .005), percentage of patients achieving ≥50% reduction in headache days (P = .015), and days of acute medication intake (P = .001). No device-related serious adverse events were reported in either REN or placebo group.
Study details: Findings are from a prospective, randomized, double-blind trial including 179 patients with migraine who were randomly assigned to receive REN (n = 95) or placebo stimulation (n = 84) every other day.
Disclosures: This study was funded by Theranica Bio-Electronics. Some authors declared receiving research, support, or educational grants, royalties, or honoraria from or serving as a consultant, on a speaker bureau, or on an advisory board for various sources, including Theranica.
Source: Tepper SJ et al. Remote electrical neuromodulation for migraine prevention: A double-blind, randomized, placebo-controlled clinical trial. Headache. 2023 (Jan 27). Doi: 10.1111/head.14469